I n recent years there has been remarkable progress in understanding the human genome. These discoveries present enormous challenges to occupational and environmental heath nurses. This article provides a framework for consideration of genetic information in the workplace and introduces issues related to genetic testing in the workplace .
To provide occupational and environmental health nurses with an overview, this article addresses the promise and characteri stics of genetic information, as well as its benefits, limits, and risks. The main focus is on genetic testing in the workplace . A short history is presented, along with a more detailed discussion of genetic screening and genetic monitoring in the workplace. The emerging problem of genetic discrimination in the workplace also is reviewed. Currently available legal protections for employees are described . Finally, implications for occupational and environmental health nursing practice are outlined and resources for further information are provided .
BACKGROUND
The mystery of the human genome is being unraveled rapidly. Individual genetic secrets, once unknow-
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Dr. Schill is Health Scientist, Occupational Safety and Health Administration, Washington, DC. 80 able, currently can be revealed through relatively simple laboratory tests. While these scientific advances hold much promise for disease prevention and treatment, misuse of information related to individual genetic makeup is an ever present threat. Nowhere is the threat of this misuse more feared than in the workplace. Genetic information obtained as a result of these new discoveries presents enormous challenges to occupational and environmental health nurses. For example, issues related to privacy and confidentiality, which always have been priorities for occupational and environmental health nurses, are even more urgent when they concern individually identifiable genetic information. Additionally, company policies addressing genetic testing in the workplace, such as those surrounding genetic screening and genetic monitoring programs, demand full consideration of complex questions.
Recently, genetic information has been defined as "information about genes, gene products , or inherited characteristics that may derive from the individual or a family member" (Rothenberg , 1997) . As such, genetic information may be thought of as a subset of health information. Virtually all health records contain some form of genetic information .
THE PROMISE OF GENETIC INFORMATION
Inside the nucleus of each somatic cell there are 23 pairs of chromosomes, with half of each pair inherited from the mother and half from the father. Each of these chromosomes contains tightly coiled, double stranded deoxyribonucleic acid (DNA), composed of many genes . Genes, short segments of DNA, are the "fundamental unites) of information storage" where instructions are encoded for the production of proteins that control inher-itance and daily cellular activity (Carroll, 1998) .
In 1990, a worldwide research effort was initiated to determine the location of the estimated 100,000 human genes and to read the three billion code letters of a representative human genome. This effort, known as the Human Genome Project (HGP), is funded jointly by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health and the U.S. Department of Energy. The original goal of the HGP was to complete a high quality sequence of the human genome by the year 2005. However, recent technological developments and experience have increased the pace of this work, and it is now anticipated this goal will be achieved by 2003 (Collins, 1998) . Understanding the human genome will lead to new approaches for prevention, diagnosis, and treatment of diseases.
For diseases with a genetic component, gene identification offers new opportunities for therapy. For example, drug therapy may be used to target the cause, not merely the symptoms, of a disease. On the other hand, gene therapy may be used to replace defective DNA. However, such therapies require extensive research prior to their general availability.
More immediately, gene identification is resulting in the development of prognostic and diagnostic tests. Prognostic tests, which may be used prior to the development of signs or symptoms, provide information related to the risk of disease. In some cases, strategies, such as increased surveillance, lifestyle changes, or drugs, may be available to prevent the disease or increase the likelihood of early diagnosis.
The HGP has rapidly accelerated the pace of gene identification and the corresponding clinical applications. For example, the gene involved in cystic fibrosis was identified first in 1989, and subsequently, 500 different mutations have been identified which can cause symptoms ranging from severe to mild to no symptoms at all (Porth, 1998) . These findings are clinically significant because cystic fibrosis is the most common fatal hereditary disease among White individuals in the United States and is the most common cause of chronic lung disease in children (Porth, 1998) . Genetic tests for high risk individuals are already commercially available for the fraction of mutations responsible for 90% of all cystic fibrosis (Porth, 1998) . Additionally, gene therapy research is being conducted in federally approved clinical trials.
However, gene identification and genetic testing do not necessarily lead immediately to clinical applications that prevent or reduce disease risk. For example, a predictive genetic test has been developed for Huntington's disease. However, there is no cure for the disease, and treatment is largely symptomatic. Presymptomatic genetic testing in this case raises many ethical, social, and legal concerns. These concerns include providing individuals with the knowledge they will develop a chronic disease characterized by dementia and other physical and psychological changes, the effect on family relationships, and the potential for discrimination related to health insurance and employment. FEBRUARY 2000. VOL. 48. NO.2 Understanding the human genome will lead to new approaches for prevention, diagnosis, and treatment ofdiseases.
Single gene mutations are responsible for more than 6,500 disorders including Huntington's disease, cystic fibrosis, sickle cell anemia, Duchenne's muscular dystrophy, and many others (Porth, 1998) . Additionally, gene mutations also are known to play a part in cancer, heart disease, diabetes, and many other common diseases of multifactorial origin. In these diseases, genetic alterations increase the risk of disease. However, the disease itself results from the interaction of genetic predisposition and environmental factors, including occupation, diet, and lifestyle.
CHARACTERISTICS OF GENETIC INFORMATION
In its most basic form, genetic information may be gleaned from a family health history or a physical examination. Routine laboratory tests that measure specific substances, such as cholesterolemia, also may suggest the genetic makeup of an individual. More sophisticated genetic information will become increasingly prevalent in health care records as individuals choose to undergo genetic testing for specific conditions and disorders. As with all health care information, the privacy and confidentiality of genetic information must be protected aggressively.
This protection is especially critical for genetic information because it has characteristics that make it particularly susceptible to abuse. According to Scanlon (1995) these characteristics include:
• Genetic information is permanent, and at present one's genotype cannot be altered.
• Genetic information has implications for other family members across generations.
• Genetic information has implications for reproductive decision making.
• Genetic information may have implications for choice of a partner, related to reproductive or quality of life issues.
• Learning that one has transmitted a genetic disorder to an offspring can affect the parent/child relationship.
• Knowledge about one's genotype or genetic risk may alter an individual's perception of societal expectations and obligations.
• The predictive nature of genetic information alters individuals' concept of their health status even when asymptomatic.
• Genetic information may be used for nonmedical reasons.
• Genetic information may result in an individual being stereotyped or labeled. • Genetic information can result in discrimination.
Additionally, because DNA is stable, biological samples for genetic testing can be stored and analyzed in the future.
BENEFITS, LIMITS, AND RISKS OF GENETIC INFORMATION
The most direct method of obtaining individual genetic information is through genetic testing. Although the terms genetic testing, genetic screening, and genetic monitoring often are used interchangeably as means to obtain genetic information, they are not the same. Genetic testing can be thought of as a "generic term referring to any assessment of heritable traits or genetic material" (Rothstein, 1984) . Genetic testing involves the examination of peripheral cells (e.g., white blood cells, red blood cells), body fluids (e.g., urine, sperm), or target tissue (e.g., bone marrow, exfoliated cells from bronchial epithelium) for biochemical, chromosomal, genetic, or other biological markers that indicate the presence or absence of a genetic disease or the susceptibility to a genetic disease or disorder. However, knowledge gained from genetic testing has inherent benefits, limits, and risks.
For individuals in families at high risk of inherited diseases or conditions, genetic testing can provide needed information to address troubling uncertainties. When test results are negative, the individual may be unburdened from the weight of the unknown. Additionally, negative test results may eliminate the need for frequent preventive examinations, such as annual colonoscopy for hereditary nonpolyposis colon cancer. On the other hand, positive test results provide information needed for decision making related to risk reduction strategies, as well as planning for the future. Positive results for some diseases, such as hemochromatosis, glaucoma, and some cancers, can alert the individual to begin preventive measures before the disease causes harm.
Genetic testing for inherited diseases and disorders also has recognized limitations. First, some familial patterns of disease may be due to environmental exposures, which can result in acquired rather than inherited susceptibility. Second, a single disease gene (e.g., cystic fibrosis) can have many different mutations, with each resulting in a different level of disease manifestation. Thus, a positive test result in this case does not necessarily mean disease is inevitable. Furthermore, because genetic testing only evaluates the more common mutations, a negative test result does not necessarily rule out all possibility of disease. Third, the predictive ability of a genetic test is based on probabilities. Therefore, it is possible for two people to have a positive test and for only one of them to develop the disease. However, perhaps the greatest limitation of genetic testing is that sometimes the ability to identify a genetic defect is far ahead of diagnostic and therapeutic capability. The classic example of this scenario is Huntington's disease.
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The most significant potential risks associated with genetic testing involve the impact the test results may have on an individual's life. An individual who has undergone genetic testing will have to cope with the newly obtained health status knowledge, the implications of this information for family members, options for future health care, and threats to the privacy and confidentiality of this information. Discrimination in health insurance, employment, and adoption proceedings all have been reported (Billings, 1992; Geller, 1996; Lapham, 1996) .
GENETIC TESTING IN THE WORKPLACE History
The idea of genetic testing in the workplace is not new. More than 60 years ago, geneticist Haldane observed:
The majority of potters do not die of bronchitis. It is quite possible that if we really understood the causation of this disease, we should find that only a fraction of potters are of a constitution which renders them liable to it. If so, we could eliminate potters' bronchitis by rejecting entrants into the pottery industry who are congenitally disposed to it (cited in Rothstein, 1989 ).
Haldane generally is credited as the first scientist to suggest using genetic testing to sort susceptible workers out of hazardous work environments. However, until recently, scientists have lacked the technical means to perform this type of sorting.
One of the earliest examples of genetic makeup affecting individuals' reactions to either a chemical agent or drug was reported in the 1950s. During the Korean conflict, some American soldiers taking the antimalarial drug primaquine experienced acute hemolytic anemia, which was attributed to their carrier status of glucose-6phosphate dehydrogenase (G6PD) deficiency (Office of Technology Assessment [OTA), 1990). These soldiers were characterized as hypersusceptible.
Glucose-6-phosphate dehydrogenase is an enzyme necessary in the glucose metabolism of the red blood cell. Based on the experience of the soldiers in the Korean conflict, it was postulated that individuals with a deficiency of G6PD also would develop acute hemolytic anemia after exposure to chemicals such as aromatic nitro and amino compounds; arsine and related metal hydrides; lead and its compounds; and several dye intermediates (Rothstein, 1984) . Stokinger (1963) published one of the first scientific journal articles advocating for the use of genetic screening to sort out individuals who were hypersusceptible to certain chemicals because of their G6PD deficiency. By the early 1970s, genetic screening for hypersusceptibility had been proposed for additional conditions, such as sickle cell trait, alpha-lantitrypsin (AAT) deficiency, and carbon disulfide sensitivity (Rothstein, 1984) .
In the 1970s, the Occupational Safety and Health Administration (OSHA), created to fulfill the mandates of the Occupational Safety and Health Act (OSH Act), had a brief but notable experience related to genetic screening of employees. At that time, OSHA promulgated 14 carcinogen standards that required a preassignment examination by a physician before an employee could be assigned to a regulated area. These standards specified the examination include the personal history of the employee, family, and occupational background, including genetic and environmental factors (OSHA, 1974) .
In February 1980, subsequent to the publication of a series of articles in The New York Times on genetic testing in the workplace, OSHA found itself embroiled in a controversy concerning the reference to genetic information in these carcinogen standards. In response, Dr. Eula Bingham, then Assistant Secretary of Labor for OSHA, issued a news release that stated, "There is absolutely no OSHA standard that requires genetic testing of any employee" (OSHA, 1980b) . Bingham said:
Exclusion of workers as a result of genetic testing runs contrary to the spirit and intent of the Occupational Safety and Health Act of 1970. It wrongly puts the burden of controlling toxic substances on the worker who is denied employment because of a supposed sensitivity. Employers should make the workplace safe for all workers, rather than deprive some workers of their livelihood in the name of safety.
The OSHA Office of Compliance Programs followed this announcement by issuing an interpretative directive to the OSHA enforcement staff in August 1980. The directive stated in part, "These provisions [of the carcinogen standards and the OSHA cancer policy] do not require genetic testing of any employee...[or] the exclusion of otherwise qualified employees from jobs on the basis of genetic testing" (OSHA, 1980a) . Furthermore, the directive explained that taking an employee's medical history must be considered a "routine part of standard medical practice ...designed to identify factors important to the employee's general health status" (OSHA, 1980a) .
The OSHA briefly reconsidered its position on genetic testing during rule making for ethylene oxide (EtO), a chemical sterilant widely used in the health care industry. The proposed rule suggested, but did not require, "screening [sic] for chromosome damage" (OSHA, 1983) . However, in the final rule, OSHA deleted the suggested genetic monitoring for chromosomal damage "because the results of such tests, as applied to an individual rather than a group, cannot be interpreted" (OSHA,1984) .
In the early 1980s, public sentiment about genetic testing in the workplace captured the interest of Congress. Prompted by concern about both the scientific and social issues surrounding genetic testing, the House Committee on Science and Technology held hearings and requested that the Office of Technology Assessment (OTA, now defunct) evaluate the role of genetic testing in the prevention of occupational disease (OTA, 1983) . As part of its evaluation, the OTA surveyed American industry, including utilities, and unions to determine the extent and nature of employer genetic monitoring and screening. The survey found genetic testing had been used by FEBRUARY 2000, VOL. 48, NO.2 
Nonoccupational genetic screening involves testing employees or prospective employees to detect general heritable conditions not associated with workplace exposures.
17 organizations in the previous 12 years but only 5 of the 17 and one other currently were conducting such testing. However, 59 organizations expressed interest in future use of genetic testing (OTA, 1983) .
Renewed Congressional interest in assessing the issues related to genetic testing in the workplace developed in the late 1980s. Several developments led to this renewed interest including (OTA, 1990): • Rapid advances in the fields of human molecular genetics and applicable biotechnologies. • The similarities between genetic testing and other types of testing in the workplace (e.g., testing for HIV). • The rapid progress of efforts to map the human genome.
In response to requests from the Senate Committee on Commerce, Science, and Transportation, the House Committee on Energy and Commerce, and the House Committee on Science, Space, and Technology, a second OTA evaluation and survey of genetic monitoring and screening in the workplace was undertaken. The results of this study, reported in 1990, revealed 12 companies currently were using genetic monitoring or screening "for research or any other reason" (OTA, 1990) . Only six companies anticipated future genetic monitoring or screening (OTA, 1990) .
Currently, OSHA does not have a formal policy related to genetic testing in the workplace. However, because the OSH Act is silent on the issue of genetic testing the possibility exists that such tests could be mandated or recommended as part of a future standard. Whether an employer could require them is unresolved.
Genetic Screening
Genetic testing, as defined above, can be implemented in the workplace to achieve distinctly different goals. Therefore, it is important to distinguish between genetic screening and genetic monitoring, as well as the different types of genetic screening (see the Figure) . Genetic screening is one type of genetic testing that may be encountered in the work environment.
Genetic screening is the one time examination of the genetic makeup of employees or prospective employees for specific inherited characteristics. In the workplace, genetic screening can be used for both nonoccupational and occupational purposes. Nonoccupational genetic screening involves testing employees or prospective employees to detect general heritable conditions not associated with workplace exposures. Screening for the Huntington's disease gene mutation is an example of nonoccupational genetic screening. Genetic screening for occupational purposes involves testing employees or prospective employees to detect the presence of genetically determined traits that render them more susceptible, or at greater risk, to an occupationally related disease if exposed to specific agents. About 50 human genetic diseases have been identified as having the potential to enhance an individual's susceptibility to toxic or carcinogenic effects of environmental agents (OTA, 1990) . Examples of these genetic diseases or disorders include G6PD deficiency, sickle cell trait, AAT deficiency, and acetylation phenotype (i.e., fast or slow acetylators).
Although genetic screening for occupationally related traits potentially can be used to ensure appropriate worksite placement of employees at greater risk of cer-84 tain occupational diseases, there are serious ethical, legal, and social concerns related to genetic testing for this purpose. These concerns focus on the potential of genetic screening as a powerful tool for sorting employees or prospective employees through discriminatory practices. In effect, such practices would create a genetic underclass of individuals unable to find employment and health insurance.
Testing for sickle cell trait is one example of the discriminatory power of genetic screening in the workplace. People of Mediterranean origin and Black individuals have a higher incidence of sickle cell anemia (OTA, 1990) . Individuals with sickle cell anemia are homozygotes, while those with sickle cell trait are heterozygotes. Currently, most clinicians believe being a carrier of sickle cell trait is not associated with any adverse health effects (Scanlon, 1995) . An estimated 9% of Black individuals are carriers of the sickle cell trait (Gaspard, 1998) .
A genetic screening program for sickle cell trait occurred at a large American chemical manufacturer in the 1970s (Brady, 1993) . According to company officials, the program was initiated at the request of a group of Black employees. The resulting information allegedly was not used for employment decisions but for the employees' own information. The company was criticized heavily for this program because it was offered only to Black employees and not to the employees of Mediterranean origin who also worked at the plant. Likewise, genetic screening for G6PD deficiency has racial and ethnic implications because deficiency occurs in approximately 16% of Black men, 11% of Mediterranean Jewish men, 1% to 2% of Greek individuals, and 1% to 8% of Sardinian individuals (OTA, 1990) .
Interest also has been expressed in genetic screening of prospective employees or employees for AAT deficiency to identify individuals at greater risk of respiratory diseases, especially emphysema, when exposed to respiratory irritants. Alpha-l-antitrypsin is a serum protein that protects the lungs from endogenous proteolytic enzymes. Homozygous individuals for AAT deficiency, while rare, have an approximately 80% lifetime risk of developing emphysema (Ashford, 1990) . Heterozygous individuals, approximately 1% to 10% of some populations, also may be at increased risk because of lowered AAT activity (Gochfeld, 1998) . However, genetic screening for AAT deficiency has been considered by some to be ethically unacceptable (Ashford, 1990) .
Even so, as of 1993, at least one large American chemical manufacturer regularly tested its employees and prospective employees for G6PD and AAT deficiencies (Brady, 1993) . According to this company, an employee with an abnormal test result may be removed from a job and relocated to either a temporary or permanent position that does not involve exposure to any type of toxic substance. Prospective employees reportedly are not refused employment but are offered employment in a location that does not include chemical exposure.
Genetic screening, as practiced by this company, raises some pertinent questions:
• Is there sufficient scientific evidence that individuals with these deficiencies are, in fact, at greater risk of disease? • Why are the levels of toxic chemicals not eliminated or reduced for all employees? • Is this genetic testing voluntary? • Do employees and prospective employees provide written informed consent prior to testing? • Are individuals with normal test results exposed to toxic substances that could otherwise be controlled or eliminated? • Are individuals with abnormal test results given a choice about their job reassignment? • Are individuals given jobs without toxic substance exposure paid at an equivalent rate? • How else does the company use this information? • Is this information considered to be confidential health information and handled accordingly? • Is appropriate genetic counseling provided for those FEBRUARY 2000, VOL. 48, NO.2 With each advance in genetic science, the introduction ofnew genetic screening tests in the workplace comes closer to reality. who undergo testing?
With each advance in genetic science, the introduction of new genetic screening tests in the workplace comes closer to reality. For example, "there is about a 50:50 split in the general population of Westem countries of a genetically determined difference in the rate, i.e., slow versus fast, at which acetyl groups attach to typical aromatic amines," an important class of occupational bladder carcinogens (Ashford, 1990) . This finding is significant because acetylated amines "appear to be relatively inactive in carcinogenesis" (Ashford, 1990 ). Therefore, people who are "slow acetylators" (i.e., have a slow N-acetyltransferase [NAT] phenotype) seem to be at higher risk for developing aromatic amine induced bladder cancer. Although commercially available genetic testing for the slow acetylator phenotype currently is not available, it may have great appeal to companies that include aromatic amine chemicals in their production process.
However, currently there is insufficient scientific evidence to justify the use of any existing genetic screening test for susceptibility as a basis for employment decisions. Genetic screening tests for susceptibility currently do not have adequate positive predictive value to determine if the individual with abnormal results is truly at increased risk of disease. According to the American Medical Association (1991), in the future there may be a very limited role for genetic screening if specific conditions are met:
•
The disease develops so rapidly that serious and irreversible illness would occur before monitoring of either the worker's exposure to the toxic substance or the worker's health status could be effective in preventing the harm.
•
The genetic screening test is highly accurate, with sufficient sensitivity and specificity to minimize the risk of false negative and false positive results. • Empirical data demonstrate that the genetic abnormality results in an unusually elevated susceptibility to occupational illness. • It would require undue cost to protect susceptible employees by lowering the level of the toxic substance in the workplace. • Testing must not be performed without the informed consent of the employee or applicant for employment.
At this time, the use of genetic screening tests likely would result in unfair discrimination against individuals
Suggested Conditions for Genetic Monitoring Programs
• Specific, written policies and procedures must be developed to manage the genetic monitoring program.
• The genetic monitoring program must be administered by a competent, licensed health care professional.
• Genetic monitoring tests must be selected for their ability to determine adverse health effects of specific toxicants in the workplace to which the employee is exposed.
• Written, voluntary, informed consent must be provided by the employee prior to participation in the genetic monitoring program.
• Individually identifiable results of the genetic monitoring tests must be treated as private, confidential health information.
• Employees must be informed, in writing, of their test results.
• Employers are entitled only to aggregated test results of the genetic monitoring program, with all personal identifiers removed from the data.
• When genetic monitoring test results are abnormal, the employer, using aggregated data, must implement engineering and work practice controls to eliminate or reduce employee exposure.
• Unless exposure to the toxic substance(s) is eliminated or controlled so it no longer presents a health risk, the employer also must provide exposed employees with appropriate personal protective equipment at no cost.
• A health restriction protection program that includes maintenance of earnings, seniority, and other employment rights and benefits must be implemented to protect employees from continued physical harm and financial loss, whenever there is a scientific basis for temporary restriction from exposure to the workplace toxicant(s).
• Employees who must be restricted permanently from further exposure to the toxic substance must receive a written opinion by a qualified health care professional that the restriction is because of an occupational injury or illness.
• The results of the genetic monitoring program must not be used by employers as a basis for employment related decisions that adversely impact or discriminate against any employee.
who have abnormal test results. Often, predisposition only manifests in disease when there is an accompanying environmental insult, such as toxic substances, viruses, 86 or other diseases. However, the influence of the environment remains the "wild card" in most cases because possession of the genetic predisposition alone may be insufficient to cause disease. For some time to come it is likely modem science will be more successful in identifying the genes and the markers than in identifying the environmental agents and doses necessary for activation of the predisposing genes .
More important, there are other ways for employers to serve their legitimate interest s. First, for example , tests of a worker 's actual capacity, versus assumption of capability, to meet the demand s of the job can be used to ensure future employability and protect public safety. Second, routine industrial hygiene monitoring of workplace exposures can be used to protect all workers, not only those who have a genetic susceptibility to a disease. Third, secondary prevention strategies (e.g., increased health surveillance) can be implemented to identify the earliest signs and symptoms of disease so health protective measures can be initiated .
Genetic Monitoring
Through occupational health surveillance, employers have a tool which can be used to prevent occupational disease or illness. An occupational illness is defined by the Bureau of Labor Statistics as "any abnormal condition or disorder, other than one resulting from an occupational injury, caused by expo sure to environmental factors associated with employment" (Bureau of Labor Statistics, 1986 ). This includes acute and chronic illnesses or diseases that can be caused by inhalation, absorption, ingestion, or direct contact. Genetic monitoring is a component of health surveillance that can be used to identify early adverse health effects that may lead to occupational illnesses.
Genetic monitoring can be defined as the periodic examination of employees to evaluate acquired modifications to their genetic material (e.g., chromosomal damage, evidence of increased occurrence of mutations) that may have developed during the course of employment because of exposure to toxic substances in the workplace. The purpo se is to identify, evaluate, and control adverse environmental expo sures in the workplace. Unlike genetic screening, genetic monitoring ascertains whether an individual's genetic material has altered over time . The assumed etiology of genetic alterations discovered through genetic monitoring is workplace exposure to hazardous substances. Such alterations are of concern becau se they could indicate increased risk of future illne sses, such as cancer. However, the precise meaning of genetic monitoring test results for individual employees related to future disease occurrence is uncertain.
Genetic monitoring is perhaps of greater value when performed on groups of employees to identify the risk for the exposed group as a whole. Evidence of genetic changes in a population of workers could be used to target specific work areas, jobs, or tasks for increased safety and health protection. In addition, the evidence could be used to indicate a need to lower exposure levels for a group exposed to a previously unknown hazard. Genetic monitoring can be viewed as an extension of other types of biological monitoring in the workplace used to detect biologic changes or assess actual individual exposures that could be associated with increased risk of occupational diseases.
Genetic monitoring should be provided, when appropriate, as part of a comprehensive health surveillance program in the workplace. Because of the unique characteristics of genetic information, as well as its benefits, limitations, and risks, genetic monitoring programs should meet very specific conditions when implemented in the workplace. The Sidebar on this page contains a list of suggested conditions.
GENETIC DISCRIMINATION IN THE WORKPLACE
Concerned about the potential for discrimination as a result of genetic testing, Billings (1992) undertook a study to determine whether incidents that may reflect genetic discrimination were reported in the workplace, in access to social services, in insurance underwriting, and in the delivery of health care. The study defined genetic discrimination as "discrimination against an individual or against members of that individual's family solely because of real or perceived differences from the 'normal' genome of that individual" (Billings, 1992) . Participants were solicited via advertisements to professionals working in genetics related fields and members of genetic disease organizations. Forty-one separate incidents of possible discrimination were reported in the responses received for the study. Of these, all but two involved insurance or employment. Seven cases reported employment discrimination that involved hiring, termination, promotion, and transfer.
An example of employment discrimination cited by Billings (1992) includes an individual who was screened for Gaucher's disease and learned he was an unaffected carrier (i.e., a heterozygote). He included this genetic information in his application for a government job. He was reportedly denied the job "because of his being a 'carrier, like sickle cell'" (Billings, 1992) . Billings (1992) also offered the following report of an employment decision made without regard to individual capability, but rather based on a diagnostic label:
In 1979 my daughter was denied employment by the [name omitted] Company because she has CMT [Charcot-Marie-Tooth disease] even though the case is not really noticeable. She had indicated on the form that she had CMT and the examiner asked her what it stood for; then, he looked it up in a medical book and denied her a job which had been offered to her by the recruiter.
Not surprisingly, several respondents in this study reported they withheld or "forgot" to mention potentially important medical or family history information to physicians, employers, or insurers (Billings, 1992) . The collection of examples captured by Billings (1992) provides evidence of genetic discrimination related to employ- FEBRUARY 2000, VOL. 48, NO.2 Genetic monitoring should be provided, when appropriate, as part ofa comprehensive health surveillance program in the workplace. ment, health insurance, and life insurance, as well as inability to change jobs or move to a different state for fear of losing insurance, and denial of applications to adopt a child.
Experiences related to genetic discrimination also have been reported by Geller (1996) in a follow up study to the work of Billings (1992) . Participants were recruited from genetic disease organizations via questionnaire. Telephone interviews were conducted for the 206 individuals who reported a genetic discrimination experience. Although most of the reported cases of discrimination involved health and life insurance companies, there also were cases that involved employers, adoption services, and blood banks. The following two cases described by Geller (1996) exemplify experiences of genetic discrimination in the workplace:
A 53 year old man was interviewed for a job with an insurance company. During his first interview, he revealed he had hemochromatosis but was asymptomatic. During the second interview, the company representatives told him that the company would be interested in hiring him, but would not be able to offer him health insurance because of his hemochromatosis. He agreed to this condition. During the third interview he was told that although they would like to hire him, they were unable to do so because of his hemochromatosis.
•
A 24 year old woman was fired from her job as a social worker shortly after her employers learned that she was at risk to develop Huntington disease. In the 8 month period prior to her termination she received three promotions and outstanding performance reviews. However, while conducting an inservice training on admitting and caring for Huntington disease patients, she revealed she had a family member with Huntington disease. Shortly afterwards, she was given a poor performance review. Her employers declined to give examples of poor performance. She was soon fired and told by a coworker that the employer was concemed about her risk to develop Huntington disease.
The issue of genetic discrimination in health insurance, life insurance, and employment also was studied by Lapham (1996) in 30 minute telephone interviews of volunteers from genetic support groups. The interview contained two questions related to employment experiences. Fifteen percent of the 332 respondents stated they had been "asked questions about genetic diseases or dis-Under this federal law, individuals with a serious, long term disease are considered to be disabled and receive the same protections against employment discrimination as other disabled individuals.
abilitie s on a job application," and 13% reported they had been denied or terminated from a job (Lapham, 1996) . Additionally, 94% of the respondents disagreed when asked if "genetic testing should be part of preemployment physical exams," and 87% reported they would not want their employers to know the results of a genetic test that found they were at high risk for a genetic disorder (Lapham , 1996) . Fear of job loss reportedly prevented 17% of the study participants from revealing genetic information to their emplo yers (Lapham, 1996) .
LEGAL PROTECTIONS FOR EMPLOYEES
Title Vll of the Civil Rights Act of 1964 provides protection against discrimination based on sex, race, color, religion, and national origin . Thus, for genetic diseases or conditions associated with particular racial or ethnic groups (e.g., sickle cell disease and trait), Title VII may provide some protection against genetic discrimination. Such protection would be based on the argument that discrimination against individual s based on racially or ethnically linked genetic diseases or conditions constitutes unlawful racial or ethnic discrimination.
However, the most far reaching protection against genetic discrimination is provided by Title I of the Americans with Disabilitie s Act (ADA, 1990) , enforced by the Equal Employment Opportunity Commission (EEOC). Under this federal law, individuals with a serious, long term disease are considered to be disabled and receive the same protections against employment discrimination as other disabled individuals . The ADA does not distinguish between genetic and other diseases.
In 1995, the EEOC made it clear the ADA "would protect individuals subjected to discrimination on the 'basis of genetic information relating to illness, disease or other disorders ", (Rothenberg , 1997) . In enforcement guidance to its investigators, EEOC instructed that an individual with a positive predictive genetic test is protected under the ADA if the employer "regards" the individual as disabled and discriminate s based on that opinion (Rothenberg, 1997) . However, this EEOC policy has not yet been tested in court and, therefore , the actual ability of the ADA to provide this protection is unknown.
In 1996, Congress enacted the Health Insurance Portability and Accountability Act (HIPAA), which took a significant step to assure continued health insurance coverage for individuals who change or leave their jobs. The HIPAA specifically prohibits the use of genetic informa-tion in the determination of eligibility or continued eligibility for health insurance coverage. Furthermore, the HIPAA provides that "genetic information shall not be treated as a 'preexisting condition in the absence of the diagnosis of the condition related to such information" (Rothenberg, 1997) . However, the HIPAA does not provide privacy protections, prohibitions against premium increases, protection from exclusion of coverage for a particular disease or condition, or protection from the imposition of lifetime caps on benefits (Rothenberg, 1997) .
Most recently, there has been active vice presidential and congressional interest in legislation specifically intended to prevent workplace discrimination based on genet ic information . However, to date federal legislation to ensure such protection has not been enacted. In the meantime, to fill the gaps left by existing federal laws, individual states have become actively interested in legislation aimed at protecting their citizens against genetic discrimination, and many states have passed such laws. Not surprisingly, there are wide variations among these state laws, including coverage of genetic abnormalities, the definition of a genetic test, prohibitions against compulsory genetic testing, genetic testing related to occupational exposures , and use of genet ic information , especially in employment related matters.
The Hereditary Susceptibility Working Group of the National Action Plan on Breast Cancer, coordinated by the Public Health Service Office on Women's Health, recently joined with the National Institutes of Health, Department of Energy Working Group on Ethical, Legal, and Social Implications of Human Genome Research to address legislative approaches and policy challenges related to genetic information in the workplace. This group developed recommendations designed to offer guidance for state and federal policymakers to protect against genetic discrimination and to promote privacy in the workplace. However, their recommendations also may be useful for corporate policymakers. The recommendations of this group were reported by Rothenberg (1997): • Employment organizations should be prohibited from using genet ic information to affect the hiring of an individual or to affect the terms, conditions, privileges, benefit s, or termination of employment unless the emplo yment organization can prove this information is job related and consistent with business necessity.
•
Employment organizations should be prohib ited from requesting or requiring collection or disclo sure of genetic information prior to a conditional offer of employment, and under all other circumstances, employment organizations should be prohibited from requesting or requiring collection or disclosure of genet ic informat ion unless the empl oyment organ ization can prove this information is job related and consistent with business necessity, or otherwise mandated by law. Written and informed consent should be required for each request , collection, or disclosure .
• Employment organizations should be restricted from access to genetic information contained in medical records released by individual s as a condition of Reprinted with permission of the American Management Association, 1999. employment, in claim s filed for reimbursement of health care costs. and other sources .
• Employment organiz ations should be prohibited from releasing geneti c information without prior written authorization of the individual. Written authorization should be required for each disclosure and include to whom the disclosure will be made.
Violators of these prov isions should be subject to strong enforcement mechanisms. including a private right of action .
IMPLICATIONS FOR PRACTICE
Many reasons exist why employers may find genetic testing of prospective employee s and employees to be attractive. Some employers may view genetic testing as a means to contain health care costs, as well as cost s associated with workers' compensation claims and decreased productivity due to sickness ab sence . However, as discussed above, genetic testing also may be a powerful tool for workplace discrimination . According to Gostin ( 199 1), a 1989 survey of 400 firms co nducted by Northwestern National Life Insurance Company found " 15% of the companies reported that by the year 2000 they planned to check the genetic statu s of prospective workers and their dependents before making employment offers."
More recently, a 1999 survey by the American Management Association (AMA) on "medical testing" in the workplace found 74 % of res ponding companies (n = 1,054) require medical examinations of newly hired and current employees (AMA, 1999) . The survey also reported approximately 51 % of the responding companies require "medical tests" of all newly hired personnel, with an additional 17.4% testing only those being hired into se lected job categories (AM A, 1999). For current employees, approximately 8% of the respondents reported the y require per iodi c medical examinations of all employees, and approximatel y 33 % require such examinations for employees in selec ted jobs (AMA. 1999 ).
Specific categories were incl uded in the 1999 AMA survey to determine the frequency of genetic testing of job applicants and employees, as well as how the test results are used. The testing categories, developed with input from the NHGRI, are pregnancy, sickle cell anemia, Huntington's disease, breast or colon cancer, susceptibility to workplace ha zards, and family medical histories. The survey results for the se testing categories are shown in Table I . Th is survey prov ide s evidence that even in the post ADA , post HIPAA environment, some employer s are conducting genetic testing of their employees and using the genetic information they obtain to make employment related deci sions.
Occupational and environmental health nurses mu st be prepared to meet the challenges presented by issue s related to genetic information in the workplace. Exam- 
Resources on Genetics and Genetic Related Issues

Name of Organization
Alliance of Genetic Support Groups American Society of Human Genetics American College of Medical Genetics Genetics Society of America National Human Genome Research Institute (NHGRI), National Institutes of Health National Society of Genetic Counselors pIes of specific areas of workplace nursing practice that will be impacted include: • Provision of direct health care, including education of individual employees and their family members related to genetic testing and collection of samples for testing. • Implementation of health promotion screening programs for diseases for which a responsible gene has been identified (e.g., mammography and BRCAl). • Participation as a team member during the genetic counseling process, both pretesting and posttesting. • Assessment of the relationship between occupational exposures at the worksite and the potential for adverse health effects either as a consequence of inherent genetic makeup or acquired genetic alterations. • Participation in company decision making related to the implementation of genetic screening and monitoring programs in the workplace. • Participation in company policymaking related to the use of genetic information and employment discrimination issues. • Participation in developing company policy related to health care and workers' compensation insurance issues related to genetic information and testing. Table 2 contains resources for obtaining additional information related to genetics and genetic issues that may be useful for occupational and environmental health nurses. To facilitate continuing education of health professionals in the field of genetics, the NHGRI, along with the American Medical Association and the American Nurses' Association, has organized a national coalition to focus on this issue. The National Coalition for Health Professional Education in Genetics held its first meeting of the full membership on March 10, 1997, during which strategies for accomplishing their mISSIOn were discussed. The AAOHN was represented at this meeting, as well as some of the related meetings. Additional information about the Coalition and its activities can be found on NHGRI's website (Table 2) .
RESOURCES FOR FURTHER INFORMATION
SUMMARY
Occupational and environmental health nurses must begin to prepare themselves for the future challenges that will be presented by the burgeoning availability of genetic information and its inevitable entry into the workplace. These challenges are complex and multifaceted, and include scientific, ethical, social, and legal concerns. The employers advised by occupational and environmental health nurses deserve the most carefully considered guidance. Likewise, the employees they serve merit the highest quality of care.
This article presents the views ofthe author and does not necessarily reflect those of the Occupational Safety and Health Administration (OSHA).
